Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Botulinum Toxin Type A (BOTOX) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium

Trial Profile

Botulinum Toxin Type A (BOTOX) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Dec 2017

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Urinary incontinence
  • Focus Therapeutic Use
  • Sponsors Allergan
  • Most Recent Events

    • 13 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 19 Feb 2015 Planned End Date changed from 1 Sep 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
    • 19 Feb 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top